ONTX Onconova Therapeutics Inc.

1.70
+0.00  (0%)
Previous Close 1.70
Open 1.70
Price To book -2.43
Market Cap 16746977
Shares 9,851,163
Volume 13,686
Short Ratio 0.92
Av. Daily Volume 211,474

SEC filingsSee all SEC filings

  1. S-3 - Registration statement under Securities Act of 1933 171214860
  2. 8-K - Current report 171211694
  3. 8-K - Current report 171196263
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171196233
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171188455

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial planned. Initiation of trial dependent on financing.
Oral Rigosertib and azacitidine
Myelodysplastic Syndromes (MDS) and Acute myeloid leukemia (AML) cancer
Phase 3 enrolling. Interim analysis due late 2017 or early 2018. Top-line data due 2H 2018.
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)

Latest News

  1. Onconova Therapeutics to Present at the LD Micro Conference in December
  2. Onconova Therapeutics Announces Data on Improved Formulation of Rigosertib and Next-Generation CDK4/6 Inhibitor at 2017 American Association of Pharmaceutical Scientists Annual Meeting
  3. Onconova Therapeutics Announces Publication of Results from Phase 1/2 Study of Rigosertib in Patients with Myelodysplastic Syndromes (MDS) and MDS Progressed to Acute Myeloid Leukemia
  4. Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 13, 2017
  5. Edited Transcript of ONTX earnings conference call or presentation 9-Nov-17 2:00pm GMT
  6. Onconova Therapeutics Announces Pricing of Public Offering of Common Stock
  7. Onconova Therapeutics Inc. to Host Earnings Call
  8. Onconova Therapeutics, Inc. Reports Business Highlights and Third Quarter 2017 Financial Results
  9. Onconova Therapeutics Inc (ONTX): How Does It Impact Your Portfolio?
  10. Onconova Therapeutics, Inc. to Provide Corporate Update and Third Quarter 2017 Financial Results
  11. Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting
  12. Today's Research Reports on Stocks to Watch: Onconova Therapeutics and Sorrento Therapeutics
  13. Onconova Therapeutics to Present Updates at Two Investor Conferences in October
  14. Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City
  15. Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 29, 2017
  16. Cellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates
  17. Onconova Therapeutics to Participate in Two Investor Conferences in September
  18. Edited Transcript of ONTX earnings conference call or presentation 15-Aug-17 1:00pm GMT
  19. Investor Network: Onconova Therapeutics Inc. to Host Earnings Call

SEC Filings

  1. S-3 - Registration statement under Securities Act of 1933 171214860
  2. 8-K - Current report 171211694
  3. 8-K - Current report 171196263
  4. 424B5 - Prospectus [Rule 424(b)(5)] 171196233
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171188455
  6. 8-K - Current report 171188449
  7. 8-K - Current report 171041277
  8. 8-K - Current report 171032423
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 171031389
  10. 8-K - Current report 17870952